Clinical Trial Update: Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant chemoradiation with gemcitabine and durvalumab followed by adjuvant gemcitabine and durvalumab in resectable or borderline …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Do-Youn Oh | Conditions: Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING